Cargando…
Reduced cGMP levels in CSF of AD patients correlate with severity of dementia and current depression
BACKGROUND: Alzheimer’s disease (AD) is a neurodegenerative disorder, primarily affecting memory. That disorder is thought to be a consequence of neuronal network disturbances and synapse loss. Decline in cognitive function is associated with a high burden of neuropsychiatric symptoms (NPSs) such as...
Autores principales: | Hesse, Raphael, Lausser, Ludwig, Gummert, Pauline, Schmid, Florian, Wahler, Anke, Schnack, Cathrin, Kroker, Katja S., Otto, Markus, Tumani, Hayrettin, Kestler, Hans A., Rosenbrock, Holger, von Arnim, Christine A. F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5343324/ https://www.ncbi.nlm.nih.gov/pubmed/28274265 http://dx.doi.org/10.1186/s13195-017-0245-y |
Ejemplares similares
-
Decreased IL-8 levels in CSF and serum of AD patients and negative correlation of MMSE and IL-1β
por: Hesse, Raphael, et al.
Publicado: (2016) -
Inhibition of cGMP-metabolizing PDEs as target for cognitive enhancement
por: Rosenbrock, Holger
Publicado: (2015) -
Increased Levels of Antigen-Bound β-Amyloid Autoantibodies in Serum and Cerebrospinal Fluid of Alzheimer’s Disease Patients
por: Maftei, Madalina, et al.
Publicado: (2013) -
NO/cGMP signalling in platelets
por: Schinner, Elisabeth, et al.
Publicado: (2009) -
cGMP and cardiac hypertrophy
por: Perera, Ruwan K, et al.
Publicado: (2015)